BiomX
(Chardan Healthcare Acquisition Corp)
In talks with BiomX
BiomX is a microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC, and cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
Rumor from
SPAC Details
SPAC Ticker : CHAC
New Ticker : PHGE
Status : Completed
Sector : Healthcare
Target :
not announced
Trust account : $ 200.0 million
Underwriters : Chardan
Lawyers :
IPO : Dec. 14, 2018
Target Announced : Jul. 16, 2019
Merger Closed : Oct. 28, 2019
Liquidation : Dec. 13, 2020
CEO & Director : Jonathan Eitan Solomon MBA
Chief Bus. Officer : Assaf Oron
Chief Devel. Officer : Dr. Merav Bassan Ph.D.
Scientific Founder : Prof. Rotem Sorek Ph.D.
Scientific Founder : Dr. Eran Elinav M.D., Ph.D.
Scientific Founder : Dr. Timothy K. Lu M.D., Ph.D.
CFO & Sec. : Marina Wolfson CPA
VP of HR : Inbal Benjamini-Elran
VP of Platform R&D : Dr. Inbar Gahali-Sass
Sr. VP & Head of Clinical Devel. : Dr. Regis A. Vilchez M.D., Ph.D.
Performance
Common Price : $ 0.31
NAV : $ 10.00
Premium to NAV : -97%
Warrant Price : $
Warrant Strike : $ 11.50
Warrant Intrinsic Value : $ 0.00
Total Return : -97%
Annualized Return : -61%
Annualized Volatility : 77%
Sharpe Ratio : -0.91
Maximum Drawdown : 97%
BiomX
BiomX is a microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC, and cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
Target announced on Jul. 16, 2019
Merger closed on Oct. 28, 2019
Valuation
Shares outstanding : 30.0 million
Current Equity Value at $ per share :
$ 5.3 million
Pro forma Equity Value at Target Announcement : $ 253.8 million
Pro forma Enterprise Value at Target Announcement : $ 0
No graph available.
Source: Investor presentation. For the latest financial projections please refer to the investor relations department of the company.